Expression of cathepsin K andmatrixmetalloproteinase 1 indicate persistent osteodestructive activity in longstanding ankylosing spondylitis

Annals of the Rheumatic Diseases

Volumn 68, Issue 8, 2009, Pages 1334-1339

  Neidhart, M ^a   Baraliakos, X ^b   Seemayer, C ^a   Zelder, C ^c   Gay, R E ^a   Michel, B A ^a   Boehm, H ^c   Gay, S ^a   Braun, J ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Zentralklinik Bad Berka   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CATHEPSIN K; ENZYME; INTERSTITIAL COLLAGENASE; OSTEOCLAST DIFFERENTIATION FACTOR; STROMELYSIN;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; ARTICULAR CARTILAGE; BONE BIOPSY; BONE DESTRUCTION; BONE MARROW; BONE TISSUE; CELL INVASION; CELL ISOLATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERVERTEBRAL DISK; INTERVERTEBRAL DISK DEGENERATION; LIGAMENT; MALE; MONONUCLEAR CELL; MULTINUCLEAR CELL; MYELITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOTOMY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SOFT TISSUE; SPINAL OSTEOTOMY; SPINE SURGERY; SURGICAL ANATOMY;

ADULT; AGED; AGED, 80 AND OVER; CATHEPSINS; FEMALE; HUMANS; INTERVERTEBRAL DISK; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; OSTEOCLASTS; SPINAL DISEASES; SPONDYLITIS, ANKYLOSING;

EID: 67651211169     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.092494     Document Type: Article

References (33)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379-90.
2. Schett G, Landewe R, van der Heijde D. Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction? Ann Rheum Dis 2007;66:709-11.
3. Lories RJ, Derese I, de Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007;56:489-97.
4. Brown MA. Non-major-histocompatibility-complex genetics of ankylosing spondylitis. Best Pract Res Clin Rheumatol 2006;20:611-21.
5. Brown MA. Human leucocyte antigen-B27 and ankylosing spondylitis. Intern Med J 2007;37:739-40.
6. Reveille JD. The genetic basis of ankylosing spondylitis. Curr Opin Rheumatol 2006;18:332-41.
7. Inman RD. Mechanisms of disease: infection and spondyloarthritis. Nat Clin Pract Rheumatol 2006;2:163-9.
8. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci 2006;11:529-43.
9. Zhu J, Yu DT. Matrix metalloproteinase expression in the spondyloarthropathies. Curr Opin Rheumatol 2006;18:364-8.
10. Yang C, Gu J, Rihl M, Baeten D, Huang F, Zhao M, et al. Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 2004;51:691-9.
11. Chen CH, Lin KC, Yu DT, Yang C, Huang F, Chen HA, et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford) 2006;45:414-20.
12. Maksymowych WP, Landewe R, Conner-Spady B, Dougados M, Mielants H, van der Tempel H, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007;56:1846-53.
13. Matsui Y, Maeda M, Nakagami W, Iwata H. The involvement of matrix metalloproteinases and inflammation in lumbar disc herniation. Spine 1998;23:863-8.
14. Teitelbaum SL. Osteoclasts: what do they do and how do they do it? Am J Pathol 2007;170:427-35.
15. Hummel KM, Petrow PK, Franz JK, Muller-Ladner U, Aicher WK, Gay RE, et al. Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. J Rheumatol 1998;25:1887-94.
16. Creemers MC, Franssen MJ, van't Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64:127-9.
17. Braun J, Bollow M, Sieper J. Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am 1998;24:697- 735.
18. Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003;48:1126-36.
19. Wanders AJ, Landewe RB, Spoorenberg A, Dougados M, van der Linden S, Mielants H, et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis Rheum 2004;50:2622-32.
20. Appel H, Loddenkemper C, Grozdanovic Z, Ebhardt H, Dreimann M, Hempfing A, et al. Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther 2006;8:R143.
21. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
22. Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNFα antibody infliximab. Rheumatology (Oxford) 2007;46:1450-3.
23. Van der Heide D, Landewe R, Deodhar A, Baker D, Han J, Xu W, et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment not inhibited with infliximab. Ann Rheum Dis 2007;66(Suppl II):85.
24. Van der Heijde D, Landewe R, Ory P, Vosse D, Zhou L, Tsuji W, et al. Two-year etanercept therapy does not inhibit radiographic progession in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65(Suppl II):81.
25. Kim HR, Kim HY, Lee SH. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology (Oxford) 2006;45:1197-200.
26. Cunnane G, FitzGerald O, Hummel KM, Gay RE, Gay S, Bresnihan B. Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis. Rheumatology (Oxford) 1999;38:34-42.
27. Yilmaz N, Ozaslan J. Biochemical bone turnover markers in patients with ankylosing spondylitis. Clin Rheumatol 2000;19:92-8.
28. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 2000;27:613-22.
29. Maksymowych WP, Jhangri GS, Fitzgerald AA, LeClercq S, Chiu P, Yan A, et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002;46:766-73.
30. Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J. Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 2005;32:1290-8.
31. Braun J, Landewe R, Hermann KG, Han J, Yan S, Williamson P, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006;54:1646-52.
32. Baraliakos X, Davis J, Tsuji W, Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 2005;52:1216-23.
33. Wanders A, Heijde DV, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52:1756-65.